|Important: This article is applicable to customers located in the United Kingdom, Denmark, Finland, The Netherlands, Sweden, or Ireland who purchased the 23andMe Ancestry Service. The 23andMe Ancestry Service was introduced on 23 October 2017.|
If you purchased the 23andMe® Ancestry Service, you have the ability to add reports on traits, wellness, genetic health risk* and carrier status* from within your 23andMe account for an additional fee.
Select the country listed on your order for more information:
- The Netherlands
- United Kingdom
The new reports will be accessible in your account immediately upon purchasing an upgrade.
The upgrade fee is non-refundable and we are unable to revoke access to these reports once purchased. You can view a full list of reports here.
*The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva collected using a collection device (Oragene·DX model OGD-500.001) for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. The relevance of each report varies based on ethnicity. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. These reports are not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication or how much of a medication you should take. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future or anything about the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For Gaucher Disease Type 1, we provide a single report that includes information on both carrier status and genetic health risk.